NASDAQ:LMNX - Luminex Stock Price, Price Target & More

$22.22 -0.20 (-0.89 %)
(As of 04/20/2018 06:24 AM ET)
Previous Close$22.42
Today's Range$22.06 - $22.54
52-Week Range$18.22 - $22.59
Volume117,600 shs
Average Volume260,080 shs
Market Capitalization$996.14 million
P/E Ratio27.01
Dividend Yield1.07%
Beta0.11

About Luminex (NASDAQ:LMNX)

Luminex logoLuminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, an automated multiplex-capable system. The company also provides MicroPlex, MagPlex, xTAG, SeroMAP, and calibration and control microspheres; xPONENT, a software suite to simplify laboratory workflow and enhance productivity; SYNCT data management software solutions; and xTAG assays and products to identify the causative agent for respiratory and gastrointestinal infections, as well as IVD kits for cystic fibrosis genotyping and pharmacogenetic assays used to profile genetic mutations related to drug metabolism. In addition, it offers MultiCode assays and products comprising HSV 1&2 assays, analyte specific reagents, and other products to detect infectious agents in clinical samples; ARIES cassettes that are self-contained assay consumables, such as ARIES HSV 1&2 assays, ARIES FLU A/B and RSV assays, ARIES group B strep assays, ARIES group A strep assays, ARIES bordetella assays, and ARIES C. difficile assays; and VERIGENE test cartridges, as well as operates as an original equipment manufacturer of custom reagents and instrumentation. The company serves pharmaceutical companies, clinical laboratories, and research and medical institutions. Luminex Corporation was founded in 1995 and is based in Austin, Texas.

Receive LMNX News and Ratings via Email

Sign-up to receive the latest news and ratings for LMNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:LMNX
CUSIP55027E10
Phone512-219-8020

Debt

Debt-to-Equity RatioN/A
Current Ratio4.97%
Quick Ratio3.87%

Price-To-Earnings

Trailing P/E Ratio27.01
Forward P/E Ratio33.67
P/E Growth2.11

Sales & Book Value

Annual Sales$306.57 million
Price / Sales3.22
Cash Flow$1.3975 per share
Price / Cash15.90
Book Value$9.94 per share
Price / Book2.24

Profitability

EPS (Most Recent Fiscal Year)$0.91
Net Income$29.42 million
Net Margins9.48%
Return on Equity8.48%
Return on Assets7.71%

Miscellaneous

Employees922
Outstanding Shares44,430,000

How to Become a New Pot Stock Millionaire

Luminex (NASDAQ:LMNX) Frequently Asked Questions

What is Luminex's stock symbol?

Luminex trades on the NASDAQ under the ticker symbol "LMNX."

How often does Luminex pay dividends? What is the dividend yield for Luminex?

Luminex announced a quarterly dividend on Wednesday, January 24th. Investors of record on Friday, March 23rd will be paid a dividend of $0.06 per share on Friday, April 13th. This represents a $0.24 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date is Thursday, March 22nd. View Luminex's Dividend History.

How were Luminex's earnings last quarter?

Luminex Co. (NASDAQ:LMNX) announced its quarterly earnings data on Monday, February, 12th. The medical instruments supplier reported $0.20 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.11. The medical instruments supplier had revenue of $78.20 million for the quarter, compared to analyst estimates of $77.33 million. Luminex had a return on equity of 8.48% and a net margin of 9.48%. The firm's quarterly revenue was up 8.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.11 EPS. View Luminex's Earnings History.

When is Luminex's next earnings date?

Luminex is scheduled to release their next quarterly earnings announcement on Monday, May, 7th 2018. View Earnings Estimates for Luminex.

What price target have analysts set for LMNX?

3 Wall Street analysts have issued 12-month price objectives for Luminex's shares. Their forecasts range from $21.00 to $24.00. On average, they expect Luminex's share price to reach $22.50 in the next twelve months. View Analyst Ratings for Luminex.

Who are some of Luminex's key competitors?

Who are Luminex's key executives?

Luminex's management team includes the folowing people:
  • Mr. Nachum Shamir, CEO, Pres & Director (Age 64)
  • Mr. Harriss T. Currie, CFO, Principal Accounting Officer, Sr. VP of Fin. & Treasurer (Age 56)
  • Mr. Richard W. Rew II, Sr. VP of Legal, Gen. Counsel & Corp. Sec. (Age 50)
  • Mr. Todd C. Bennett, Sr. VP of Global Sales & Customer Operations (Age 48)
  • Mr. Randall J. Myers, Sr. VP of Global Manufacturing & Quality (Age 56)

Has Luminex been receiving favorable news coverage?

Media headlines about LMNX stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Luminex earned a daily sentiment score of 0.09 on Accern's scale. They also assigned media stories about the medical instruments supplier an impact score of 47.00 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Luminex?

Shares of LMNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Luminex's stock price today?

One share of LMNX stock can currently be purchased for approximately $22.22.

How big of a company is Luminex?

Luminex has a market capitalization of $996.14 million and generates $306.57 million in revenue each year. The medical instruments supplier earns $29.42 million in net income (profit) each year or $0.91 on an earnings per share basis. Luminex employs 922 workers across the globe.

How can I contact Luminex?

Luminex's mailing address is 12212 TECHNOLOGY BLVD, AUSTIN TX, 78727. The medical instruments supplier can be reached via phone at 512-219-8020 or via email at [email protected]


MarketBeat Community Rating for Luminex (LMNX)

Community Ranking:  1.7 out of 5 (star)
Outperform Votes:  136 (Vote Outperform)
Underperform Votes:  264 (Vote Underperform)
Total Votes:  400
MarketBeat's community ratings are surveys of what our community members think about Luminex and other stocks. Vote "Outperform" if you believe LMNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LMNX will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Luminex (NASDAQ:LMNX) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
3 Wall Street analysts have issued ratings and price targets for Luminex in the last 12 months. Their average twelve-month price target is $22.50, suggesting that the stock has a possible upside of 1.26%. The high price target for LMNX is $24.00 and the low price target for LMNX is $21.00. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.332.332.251.75
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
3 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $22.50$22.50$21.3333$19.3333
Price Target Upside: 1.26% upside16.52% upside6.03% upside5.51% downside

Luminex (NASDAQ:LMNX) Consensus Price Target History

Price Target History for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ:LMNX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/13/2018William BlairReiterated RatingMarket PerformLowView Rating Details
1/5/2018BTIG ResearchInitiated CoverageBuy -> Buy$24.00HighView Rating Details
10/20/2017Jefferies GroupReiterated RatingHold$21.00N/AView Rating Details
2/7/2017Piper JaffrayLower Price TargetNeutral$20.00 -> $19.00N/AView Rating Details
1/18/2017Deutsche BankReiterated RatingSell$18.00N/AView Rating Details
10/12/2016Avondale PartnersInitiated CoverageOutperform$27.00N/AView Rating Details
8/18/2016JPMorgan ChaseUpgradeUnderweight -> Neutral$18.00 -> $22.00N/AView Rating Details
5/3/2016Leerink SwannReiterated RatingHold$22.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Luminex (NASDAQ:LMNX) Earnings History and Estimates Chart

Earnings by Quarter for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ:LMNX) Earnings Estimates

2018 EPS Consensus Estimate: $0.57
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.18$0.18$0.18
Q2 20181$0.15$0.15$0.15
Q3 20181$0.11$0.11$0.11
Q4 20181$0.13$0.13$0.13

Luminex (NASDAQ LMNX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/7/2018$0.18N/AView Earnings Details
2/12/2018Q4 2017$0.09$0.20$77.33 million$78.20 millionViewListenView Earnings Details
10/30/2017Q3 2017$0.19$0.25$74.38 million$74.14 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.09$0.20$75.45 million$76.50 millionViewListenView Earnings Details
5/1/2017Q1 2017$0.16$0.28$74.25 million$77.80 millionViewListenView Earnings Details
2/6/2017Q4 2016$0.09$0.11$70.92 million$72.30 millionViewListenView Earnings Details
10/31/2016Q316$0.12$0.21$68.90 million$71.20 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.33$61.20 million$64.20 millionViewListenView Earnings Details
5/2/2016Q116$0.14$0.29$60.98 million$63.00 millionViewListenView Earnings Details
2/1/2016Q4 2015$0.17$0.48$59.93 million$60.45 millionViewN/AView Earnings Details
11/2/2015Q315$0.11$0.17$57.24 million$60.60 millionViewListenView Earnings Details
8/3/2015Q215$0.12$0.27$57.01 million$58.90 millionViewListenView Earnings Details
5/4/2015Q115$0.12$0.23$56.50 million$57.70 millionViewListenView Earnings Details
2/2/2015Q414$0.12$0.19$58.31 million$58.10 millionViewListenView Earnings Details
10/27/2014Q314$0.10$0.27$56.60 million$56.68 millionViewListenView Earnings Details
7/28/2014Q214$0.10$0.20$55.90 million$55.50 millionViewListenView Earnings Details
4/28/2014Q114$0.12$0.24$55.31 million$56.60 millionViewListenView Earnings Details
2/3/2014Q413$0.07$0.21$56.63 million$55.20 millionViewListenView Earnings Details
11/4/2013Q313$0.11$0.02$54.67 million$50.80 millionViewListenView Earnings Details
7/29/2013Q2 2013$0.10$0.17$54.16 million$54.30 millionViewListenView Earnings Details
4/29/2013Q1 2013$0.08$0.19$51.94 million$53.20 millionViewListenView Earnings Details
2/4/2013Q4 2012$0.08$0.12$54.09 million$55.53 millionViewListenView Earnings Details
10/29/2012Q312$0.06$0.04$51.26 million$50.00 millionViewN/AView Earnings Details
7/30/2012$0.08$0.07ViewN/AView Earnings Details
4/30/2012$0.09$0.08ViewN/AView Earnings Details
2/6/2012$0.07$0.11ViewN/AView Earnings Details
11/1/2011$0.05$0.05ViewN/AView Earnings Details
8/8/2011$0.06$0.11ViewN/AView Earnings Details
5/9/2011$0.06$0.11ViewN/AView Earnings Details
2/7/2011$0.05$0.07ViewN/AView Earnings Details
11/4/2010Q3 2010$0.04($0.02)ViewN/AView Earnings Details
8/5/2010Q2 2010$0.05$0.02ViewN/AView Earnings Details
5/6/2010Q1 2010$0.05$0.05ViewN/AView Earnings Details
2/4/2010Q4 2009$0.07$0.12ViewN/AView Earnings Details
11/4/2009Q3 2009$0.07($0.02)ViewN/AView Earnings Details
8/6/2009Q2 2009$0.07$0.03ViewN/AView Earnings Details
5/7/2009Q1 2009$0.06$0.04ViewN/AView Earnings Details
2/5/2009Q4 2008$0.06$0.05ViewN/AView Earnings Details
11/6/2008Q3 2008$0.01$0.08ViewN/AView Earnings Details
8/7/2008Q2 2008($0.02)($0.03)ViewN/AView Earnings Details
5/8/2008Q1 2008($0.03)($0.03)ViewN/AView Earnings Details
2/7/2008Q4 2007($0.04)$0.10ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Luminex (NASDAQ:LMNX) Dividend Information

Luminex pays an annual dividend of $0.24 per share, with a dividend yield of 1.08%. LMNX's most recent quarterly dividend payment was Friday, April 13. Luminex pays out 26.37% of its earnings out as a dividend.
Most Recent Dividend:4/13/2018
Annual Dividend:$0.24
Dividend Yield:1.08%
Payout Ratio:26.37% (Trailing 12 Months of Earnings)
36.36% (Based on This Year's Estimates)
31.58% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ:LMNX) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/24/2018Quarterly$0.061.14%3/22/20183/23/20184/13/2018
12/14/2017quarterly$0.061.18%12/21/201712/22/20171/12/2018
9/12/2017Quarterly$0.061.2%9/21/20179/22/201710/13/2017
5/25/2017quarterly$0.061.18%6/21/20176/23/20177/14/2017
2/22/2017special$0.063/22/20173/24/20174/14/2017
(Data available from 1/1/2013 forward)

Insider Trades

Luminex (NASDAQ LMNX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.40%
Institutional Ownership Percentage: 80.75%
Insider Trading History for Luminex (NASDAQ:LMNX)
Institutional Ownership by Quarter for Luminex (NASDAQ:LMNX)

Luminex (NASDAQ LMNX) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/18/2017G Walter Loewenbaum IIDirectorSell10,503$20.61$216,466.83564,217View SEC Filing  
12/14/2017G Walter Loewenbaum IIDirectorSell31,739$20.49$650,332.11574,720View SEC Filing  
12/12/2017G Walter Loewenbaum IIDirectorSell39,456$20.40$804,902.40651,736View SEC Filing  
11/16/2017G Walter Loewenbaum IIDirectorSell50,000$21.79$1,089,500.00View SEC Filing  
8/23/2017Robert J CresciDirectorSell19,631$18.98$372,596.38260,358View SEC Filing  
5/30/2017G Walter Loewenbaum IIDirectorSell25,000$20.07$501,750.00713,896View SEC Filing  
5/23/2017G Walter Loewenbaum IIDirectorSell25,000$20.23$505,750.00738,896View SEC Filing  
5/18/2017G Walter Loewenbaum IIDirectorSell25,000$20.80$520,000.00View SEC Filing  
1/26/2017G Walter Loewenbaum IIDirectorSell20,000$19.75$395,000.00766,240View SEC Filing  
1/19/2017G Walter Loewenbaum IIDirectorSell20,000$19.82$396,400.00766,240View SEC Filing  
1/12/2017G Walter Loewenbaum IIDirectorSell20,000$20.43$408,600.00766,240View SEC Filing  
1/5/2017G Walter Loewenbaum IIDirectorSell20,000$20.32$406,400.00766,240View SEC Filing  
12/29/2016G Walter Loewenbaum IIDirectorSell20,000$20.27$405,400.00766,240View SEC Filing  
11/28/2016G Walter Loewenbaum IIDirectorSell50,000$20.57$1,028,500.00749,414View SEC Filing  
11/15/2016Kevin M McnamaraDirectorSell12,000$21.03$252,360.0067,274View SEC Filing  
11/3/2016Harriss T. CurrieSVPBuy4,100$18.20$74,620.00View SEC Filing  
11/3/2016Nachum ShamirCEOBuy6,000$18.22$109,320.00105,010View SEC Filing  
1/4/2016G Walter Loewenbaum IIDirectorSell41,056$20.53$842,879.68788,583View SEC Filing  
12/31/2015G Walter Loewenbaum IIDirectorSell18,944$21.65$410,137.60829,639View SEC Filing  
12/16/2015Russell W. BradleyCMOSell6,514$22.75$148,193.50104,067View SEC Filing  
5/28/2015Nachum ShamirCEOBuy6,000$16.73$100,380.00View SEC Filing  
5/27/2015G Walter Loewenbaum IIDirectorBuy38,966$16.71$651,121.86View SEC Filing  
2/5/2015Fred C Goad JrDirectorSell25,000$15.46$386,500.00View SEC Filing  
10/8/2014Russell W BradleySVPSell5,000$20.50$102,500.00View SEC Filing  
5/15/2014Patrick BalthropCEOSell70,000$17.69$1,238,300.00486,367View SEC Filing  
5/12/2014Kevin McnamaraDirectorSell5,000$17.95$89,750.0060,614View SEC Filing  
5/9/2014Jim KeverDirectorSell5,000$17.52$87,600.00187,745View SEC Filing  
5/7/2014Patrick BalthropCEOSell32,575$17.63$574,297.25556,367View SEC Filing  
5/6/2014Patrick BalthropCEOSell60,000$18.28$1,096,800.00545,833View SEC Filing  
5/2/2014Fred Goad, Jr.DirectorSell50,000$18.86$943,000.00312,745View SEC Filing  
5/2/2014Patrick BalthropCEOSell55,000$19.05$1,047,750.00524,937View SEC Filing  
5/1/2014David ReiterSVPSell15,000$19.09$286,350.0060,400View SEC Filing  
5/1/2014Harriss CurrieCFOSell11,000$19.08$209,880.00186,576View SEC Filing  
9/23/2013Harriss CurrieCFOSell30,000$19.88$596,400.00167,748View SEC Filing  
9/17/2013Harriss CurrieCFOSell30,000$19.87$596,100.00167,748View SEC Filing  
9/13/2013Michael PintekSVPSell3,000$20.00$60,000.0054,392View SEC Filing  
8/30/2013G Walter Loewenbaum IIDirectorBuy6,034$20.62$124,421.08864,662View SEC Filing  
8/28/2013G Walter Loewenbaum IIDirectorBuy20,000$20.76$415,200.00858,628View SEC Filing  
8/16/2013Timothy DehneVPSell32,297$20.66$667,256.0220,441View SEC Filing  
8/15/2013G Walter Loewenbaum IIDirectorBuy10,000$20.82$208,200.00838,628View SEC Filing  
8/14/2013Timothy DehneVPSell1,793$21.21$38,029.5320,441View SEC Filing  
8/9/2013G Walter Loewenbaum IIDirectorBuy4,600$21.17$97,382.00828,628View SEC Filing  
8/2/2013G Walter Loewenbaum IIDirectorBuy27,000$20.01$540,270.00823,628View SEC Filing  
8/2/2013Patrick J BalthropCEOSell68,048$20.01$1,361,640.48View SEC Filing  
8/1/2013David S ReiterSVPSell15,000$20.00$300,000.00View SEC Filing  
8/1/2013Thomas W EricksonDirectorSell20,000$20.00$400,000.00View SEC Filing  
5/24/2013Fred C Goad JrDirectorBuy11,250$18.25$205,312.50View SEC Filing  
5/17/2013G Walter Loewenbaum IIDirectorBuy13,000$18.37$238,810.00791,628View SEC Filing  
5/16/2013Fred C Goad JrDirectorBuy8,000$18.18$145,440.00View SEC Filing  
5/15/2013G Walter Loewenbaum IIDirectorBuy39,500$18.32$723,640.00View SEC Filing  
5/10/2013David S ReiterSVPSell10,000$18.26$182,600.00View SEC Filing  
5/10/2013G Walter Loewenbaum IIDirectorBuy19,000$18.13$344,470.00View SEC Filing  
5/9/2013G Walter Loewenbaum IIDirectorBuy28,300$17.21$487,043.00View SEC Filing  
5/7/2013G Walter Loewenbaum IIDirectorBuy64,935$17.17$1,114,933.95View SEC Filing  
5/3/2013G Walter Loewenbaum IIDirectorBuy24,765$17.02$421,500.30View SEC Filing  
9/4/2012David S ReiterVPSell10,000$20.00$200,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Luminex (NASDAQ LMNX) News Headlines

Source:
DateHeadline
Luminex (LMNX) Upgraded at BidaskClubLuminex (LMNX) Upgraded at BidaskClub
www.americanbankingnews.com - April 19 at 9:58 AM
Luminex (LMNX) Upgraded by ValuEngine to BuyLuminex (LMNX) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - April 17 at 10:29 AM
Luminex Corporation First Quarter Earnings Release Scheduled for May 7, 2018Luminex Corporation First Quarter Earnings Release Scheduled for May 7, 2018
finance.yahoo.com - April 16 at 4:24 PM
Luminex (LMNX) Stock Rating Lowered by BidaskClubLuminex (LMNX) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 11 at 9:30 PM
Luminex Co. (LMNX) Receives Average Recommendation of "Buy" from AnalystsLuminex Co. (LMNX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 11 at 11:37 AM
Luminex (LMNX) Upgraded by ValuEngine to "Hold"Luminex (LMNX) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - April 9 at 11:35 AM
$80.40 Million in Sales Expected for Luminex Co. (LMNX) This Quarter$80.40 Million in Sales Expected for Luminex Co. (LMNX) This Quarter
www.americanbankingnews.com - April 7 at 4:23 AM
 Analysts Expect Luminex Co. (LMNX) Will Announce Earnings of $0.21 Per Share Analysts Expect Luminex Co. (LMNX) Will Announce Earnings of $0.21 Per Share
www.americanbankingnews.com - April 5 at 9:50 AM
Luminex (LMNX) Lifted to Sell at BidaskClubLuminex (LMNX) Lifted to Sell at BidaskClub
www.americanbankingnews.com - March 29 at 4:10 PM
Global Molecular Diagnostics Equipment Market Opportunities 2018: Sequenom, Foundation Medicine, Luminex CorporationGlobal Molecular Diagnostics Equipment Market Opportunities 2018: Sequenom, Foundation Medicine, Luminex Corporation
www.marketwatch.com - March 26 at 9:55 AM
Luminex (LMNX) Product Portfolio Solid, Competition RifeLuminex (LMNX) Product Portfolio Solid, Competition Rife
www.zacks.com - March 26 at 9:55 AM
BidaskClub Downgrades Luminex (LMNX) to SellBidaskClub Downgrades Luminex (LMNX) to Sell
www.americanbankingnews.com - March 24 at 4:30 PM
 Analysts Anticipate Luminex Co. (LMNX) Will Post Quarterly Sales of $80.40 Million Analysts Anticipate Luminex Co. (LMNX) Will Post Quarterly Sales of $80.40 Million
www.americanbankingnews.com - March 21 at 9:51 AM
Zacks: Analysts Expect Luminex Co. (LMNX) to Announce $0.21 EPSZacks: Analysts Expect Luminex Co. (LMNX) to Announce $0.21 EPS
www.americanbankingnews.com - March 19 at 5:12 AM
With An ROE Of 6.72%, Can Luminex Corporation (NASDAQ:LMNX) Catch Up To The Industry?With An ROE Of 6.72%, Can Luminex Corporation (NASDAQ:LMNX) Catch Up To The Industry?
finance.yahoo.com - March 18 at 9:25 AM
Luminex Co. (LMNX) Receives Average Rating of "Buy" from BrokeragesLuminex Co. (LMNX) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - March 17 at 11:38 AM
Luminex Co. Plans Quarterly Dividend of $0.06 (LMNX)Luminex Co. Plans Quarterly Dividend of $0.06 (LMNX)
www.americanbankingnews.com - March 17 at 10:02 AM
Luminex Corporation to Present at the Barclays Global Healthcare ConferenceLuminex Corporation to Present at the Barclays Global Healthcare Conference
www.prnewswire.com - March 8 at 2:23 PM
$80.43 Million in Sales Expected for Luminex Co. (LMNX) This Quarter$80.43 Million in Sales Expected for Luminex Co. (LMNX) This Quarter
www.americanbankingnews.com - March 4 at 6:58 AM
Systematic Financial Management LP Lowers Stake in Luminex Co. (LMNX)Systematic Financial Management LP Lowers Stake in Luminex Co. (LMNX)
www.americanbankingnews.com - March 2 at 8:17 PM
Luminex Co. (LMNX) Position Cut by Martingale Asset Management L PLuminex Co. (LMNX) Position Cut by Martingale Asset Management L P
www.americanbankingnews.com - March 2 at 7:03 AM
Luminex Corp (LMNX) Files 10-K for the Fiscal Year Ended on December 31, 2017Luminex Corp (LMNX) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 26 at 4:57 PM
Luminex Co. (LMNX) Position Cut by Smith Asset Management Group LPLuminex Co. (LMNX) Position Cut by Smith Asset Management Group LP
www.americanbankingnews.com - February 26 at 3:02 PM
American Century Companies Inc. Increases Holdings in Luminex Co. (LMNX)American Century Companies Inc. Increases Holdings in Luminex Co. (LMNX)
www.americanbankingnews.com - February 25 at 4:06 AM
Luminex (LMNX) Upgraded to "Hold" at BidaskClubLuminex (LMNX) Upgraded to "Hold" at BidaskClub
www.americanbankingnews.com - February 24 at 10:54 PM
Luminex Co. (LMNX) Given Average Rating of "Hold" by BrokeragesLuminex Co. (LMNX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 20 at 11:30 AM
Research Analysts Issue Forecasts for Luminex Co.s Q1 2018 Earnings (LMNX)Research Analysts Issue Forecasts for Luminex Co.'s Q1 2018 Earnings (LMNX)
www.americanbankingnews.com - February 14 at 6:48 AM
Luminex (LMNX) Earns "Market Perform" Rating from William BlairLuminex (LMNX) Earns "Market Perform" Rating from William Blair
www.americanbankingnews.com - February 13 at 12:26 PM
Luminex (LMNX) Announces  Earnings ResultsLuminex (LMNX) Announces Earnings Results
www.americanbankingnews.com - February 12 at 5:20 PM
Luminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial ResultsLuminex Corporation Reports Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - February 12 at 4:32 PM
Luminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare ConferenceLuminex Corporation To Present At LEERINK Partners 7th Annual Global Healthcare Conference
finance.yahoo.com - February 6 at 9:06 AM
Luminex (LMNX) Scheduled to Post Earnings on MondayLuminex (LMNX) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - February 5 at 1:10 AM
9 Stocks Ken Fisher Continues to Buy9 Stocks Ken Fisher Continues to Buy
finance.yahoo.com - January 31 at 4:28 PM
Luminex (LMNX) Cut to "Strong Sell" at BidaskClubLuminex (LMNX) Cut to "Strong Sell" at BidaskClub
www.americanbankingnews.com - January 29 at 12:28 AM
Luminex Co. (LMNX) Receives Average Recommendation of "Hold" from BrokeragesLuminex Co. (LMNX) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 26 at 11:57 AM
Luminex Corporation Declares First Quarter Cash DividendLuminex Corporation Declares First Quarter Cash Dividend
finance.yahoo.com - January 24 at 4:44 PM
Luminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare ConferenceLuminex Announces Preliminary Revenue for the Fourth Quarter and Full Year 2017; Company to Present at 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 7 at 5:09 PM
Luminex (LMNX) Research Coverage Started at BTIG ResearchLuminex (LMNX) Research Coverage Started at BTIG Research
www.americanbankingnews.com - January 5 at 8:54 AM
BidaskClub Downgrades Luminex (LMNX) to Strong SellBidaskClub Downgrades Luminex (LMNX) to Strong Sell
www.americanbankingnews.com - December 27 at 7:26 PM
$76.74 Million in Sales Expected for Luminex Co. (LMNX) This Quarter$76.74 Million in Sales Expected for Luminex Co. (LMNX) This Quarter
www.americanbankingnews.com - December 27 at 5:08 PM
Abbott Rides High on FDA Approvals & Buyouts Amid HeadwindsAbbott Rides High on FDA Approvals & Buyouts Amid Headwinds
finance.yahoo.com - December 22 at 10:12 AM
Luminex Co. (LMNX) Director Sells $216,466.83 in StockLuminex Co. (LMNX) Director Sells $216,466.83 in Stock
www.americanbankingnews.com - December 21 at 2:20 PM
Luminex (LMNX) versus Hansen Medical (HNSN) Financial ReviewLuminex (LMNX) versus Hansen Medical (HNSN) Financial Review
www.americanbankingnews.com - December 21 at 1:12 PM
PerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3BPerkinElmer (PKI) Closes EUROIMMUN Acquisition for $1.3B
finance.yahoo.com - December 20 at 10:08 AM
Why Luminex Corporation (NASDAQ:LMNX) Delivered An Inferior ROE Compared To The IndustryWhy Luminex Corporation (NASDAQ:LMNX) Delivered An Inferior ROE Compared To The Industry
finance.yahoo.com - December 17 at 10:03 AM
Insider Selling: Luminex Co. (LMNX) Director Sells 31,739 Shares of StockInsider Selling: Luminex Co. (LMNX) Director Sells 31,739 Shares of Stock
www.americanbankingnews.com - December 15 at 6:06 PM
Luminex (LMNX) vs. Its Competitors Financial ComparisonLuminex (LMNX) vs. Its Competitors Financial Comparison
www.americanbankingnews.com - December 15 at 1:34 PM
Here's Why You Should Invest in Illumina (ILMN) Stock NowHere's Why You Should Invest in Illumina (ILMN) Stock Now
finance.yahoo.com - December 15 at 10:31 AM
Luminex Co. (LMNX) Announces $0.06 Quarterly DividendLuminex Co. (LMNX) Announces $0.06 Quarterly Dividend
www.americanbankingnews.com - December 14 at 5:56 PM
Luminex Co. (LMNX) Director Sells $804,902.40 in StockLuminex Co. (LMNX) Director Sells $804,902.40 in Stock
www.americanbankingnews.com - December 13 at 5:46 PM

SEC Filings

Luminex (NASDAQ:LMNX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Luminex (NASDAQ:LMNX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Luminex (NASDAQ LMNX) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.